Review Article
Icaritin: A Novel Natural Candidate for Hematological Malignancies Therapy
Table 1
Apoptotic activity of icaritin and the underlying signaling pathways in hematological cancer cells.
| Cell lines | Pathway of apoptosis | Molecular markers | Signaling pathways | References |
| Burkitt lymphoma (Raji, P3HR-1) | extrinsic | activated caspase-8,-9 PARP decreased Bcl-2 and c-myc | Inhibition of Bcl-2 and c-myc | [44] |
| Multiple myeloma (U266) | intrinsic | activated caspase-3,-9, Bak, Bax decreased Bcl-X1 | inhibition of IL-6/JAK2/STAT3 Up-regulation of JNK-c-jun | [41] |
| Extranodal NK/T cell lymphoma (SNK-10, SNT-8) | intrinsic | activated caspase-3,-9, Bax decreased Bcl-2, p-Bad | inhibition of JAK/STAT3 and PI3K/Akt | [42] |
| Chronic myeloid leukemia (K562) | intrinsic | activated caspase-3,-9 decreased Apaf-1, release of cytochrome C | inhibition of MAPK/ERK and PI3K/AKT up-regulation of JNK/c-jun | [40] |
| Acute myeloid leukemia (NB4, HL60, U937 Bone marrow mononuclear cell) | intrinsic | activated caspase-3,-7,-9, PARP | inhibition of MAPK/ERK/JNK and JAK2/STAT3 /AKT | [43] |
|
|